Blow For Sweden's BioArctic As AbbVie Exits Parkinson's Pact
US Major Pulls Out Of Alpha Synuclein Space
Novartis and Roche may be committed to the target, but AbbVie has decided that its efforts in Parkinson's will not include a Phase II trial of its Swedish partner's alpha synuclein drug.
